|
Match
|
Document |
Document Title |
|
|
US20090053317 |
MICROPARTICULATE SYSTEMS FOR THE ORAL ADMINISTRATION OF BIOLOGICALLY ACTIVE SUBSTANCES
The present invention relates to gastroresistant and enterosoluble microparticulate systems for the encapsulation of biologically active substances selected from: flavonoids, vitamins,... |
|
|
US20070207958 |
Method of treatment of diabetes and/or obesity with reduced nausea side effect
The present invention provides methods of administering an insulinotropic peptide in an amount effective to treat a disorder or condition while reducing nausea side effect by administering to a... |
|
|
US20140072558 |
Activin Receptor Type II B Inhibitors Comprising DLK1 Extracellular Water-Soluble Domain
The present invention relates to an activin receptor type II B (ACVR2B) inhibitor which comprises the delta-like 1 homolog (DLK1) extracellular water-soluble domain. More specifically, the present... |
|
|
US20110015123 |
Modulation of GLUT4 Gene Promoter activity BY AHNAK
Agents capable of alleviating AHNAK phosphoprotein-mediated repression of GLUT4 gene expression are useful for prevention, treatment, and/or alleviation of insulin resistance associated with... |
|
|
US20100166770 |
ANTAGONISTS OF BACTERIAL SEQUENCES
The present invention refers to antagonist molecules, particularly nucleic acid effector molecules directed against a bacterial RNA. |
|
|
US20090093414 |
Hyaluronic Acid-Methotrexate Conjugate
An object of the present invention is to provide a hyaluronic acid-methotrexate conjugate useful as a therapeutic drug for joint disorders. There is provided a hyaluronic acid-methotrexate... |
|
|
US20130165369 |
METHOD OF TREATING OBESITY AND METABOLIC DISORDERS RELATED TO EXCESS ADIPOSE TISSUE BY ADMINISTRATION OF sFRP-- PEPTIDE
Disclosed is a method of reducing the amount of adipose tissue in a subject comprising administering to the subject an amount of an sFRP-5 peptide effective to reduce the amount of adipose tissue,... |
|
|
US20110046045 |
Method of treating obesity and metabolic disorders related to excess adipose tissue by administration of sFRP-5 peptide
Disclosed is a method of reducing the amount of adipose tissue in a subject comprising administering to the subject an amount of an sFRP-5 peptide effective to reduce the amount of adipose tissue,... |
|
|
US20120322723 |
USE OF INTERLEUKIN-1 RECEPTOR ANTAGONIST FOR PREPARING MEDICAMENT FOR PREVENTING OR TREATING EPITHELIUM TRAUMA OF INTESTINAL MUCOSA
The invention provides a use of the interleukin-1 receptor antagonist protein for preparing a medicament for preventing or treating epithelium trauma of the intestinal mucosa, wherein the protein... |
|
|
US20080269114 |
Y4 Selective Receptor Agonists For Thereapeutic Interventions
Y4 receptor agonists selective for the Y4 receptor over the Y1 and Y2 receptors are useful for treatment of conditions responsive to activation of Y4 receptors. The Y4 selective agonists (a) are... |
|
|
US20140308235 |
METAP2 Inhibitors and Methods of Treating Obesity
The present invention relates to modified or polymer conjugated MetAP2 inhibitors. The present invention also relates to methods of preventing, inducing, causing or increasing weight loss,... |
|
|
US20090214657 |
Orally Absorbed Pharmaceutical Formulation and Method of Administration
A pharmaceutical formulation for absorption through oral mucosae comprising an effective amount of (a) a pharmaceutical agent in mixed micellar form, (b) at least one micelle-forming compound... |
|
|
US20110312873 |
N-TERMINALLY MODIFIED TETRAPEPTIDE DERIVATIVES HAVING A C-TERMINAL ARGININE MIMETIC
The invention refers to multibasic, N-terminally modified tetrapeptide mimetics with a C-terminal P1-arginine mimetic, methods for their production and use for therapy and prophylaxis of diseases,... |
|
|
US20090221489 |
Water-Soluable Films Comprising Low-Viscosity Alginates
A film comprising as a film-forming agent an alginate salt of monovalent cation or a mixture of alginate salts containing at least one alginate salt of monovalent cation, the film-forming agent... |
|
|
US20090137473 |
INHIBITION OF MICROTUBULE PROTRUSION IN CANCER CELLS
The present invention generally concerns microtubule protrusions in cancer cells, including detached cancer cells, and inhibition of the protrusions. In particular aspects, the inhibition of the... |
|
|
US20070135335 |
Therapeutic molecules
The present invention relates generally to a ligand for a protein associated with modulating obesity, diabetes and metabolic energy levels in animals including humans. More particularly, the... |
|
|
US20120251457 |
METHODS AND COMPOSITIONS FOR MODULATING ADIPOCYTE FUNCTION
Methods and compositions for treating obesity and related disorders. The methods include the use of BMP-2, -4, -6 and -7. |
|
|
US20110117049 |
Methods and Compositions for Modulating Adipocyte Function
Methods and compositions for treating obesity and related disorders. The methods include the use of BMP-2, -4, -6 and -7. |
|
|
US20130196904 |
PHARMACEUTICAL COMPOSITION FOR TREATING MEDICAL CONDITIONS AND A METHOD FOR TREATING ALIMENTARY DISORDERS AND RELATED DISEASES
The present invention refers to a pharmaceutical compositions that comprises an active ingredient, such as a peptide, which acts as an antagonist and/or inverse agonist of a G protein-coupled... |
|
|
US20050048120 |
Dosage form comprising self-destructive membrane
A sustained release dosage form is disclosed, which dosage form comprises an interior lipophilic membrane, and an exterior hydrophilic membrane comprising a peptide, that surround a composition... |
|
|
US20070203061 |
Adiponectin expression-inducing agents and uses thereof
The present invention provides adiponectin expression-inducing agents, and therapeutic agents using the same for obesity and obesity-related diseases such as cardiovascular diseases or metabolic... |
|
|
US20120108504 |
LEPTIN AGONIST AND METHODS OF USE
Peptides are provided having leptin receptor agonist activity. The peptides are useful for treating obesity, type II diabetes, appetite control after bariatric surgery, insulin resistance,... |
|
|
US20130252884 |
FGF21 ANALOGUES AND DERIVATIVES
Novel analogues of Fibroblast Growth Factor 21 (FGF21), derivatives thereof having a modifying moiety covalently attached thereto, and pharmaceutical use of these analogues and derivatives, in... |
|
|
US20070213274 |
Novel genes and markers associated with high-density lipoprotein-cholesterol (HDL-C)
This invention relates to the therapeutic, diagnostic and pharmacogenetic use of nucleic acids and proteins involved in the regulation of human high density lipoprotein (HDL) and pharmaceutical... |
|
|
US20100144624 |
PROCESS FOR THE PREPARATION OF COMPOSITIONS OF AT1 RECEPTOR ANTAGONIST AND ANGIOTENSIN-(1-7)
We describe preparation of compounds of an AT1 receptor antagonist(s) and Angiotensin (1-7), for example, Angiotensin-(1-7) losartanate and analogues thereof, and/or mixtures of these systems,... |
|
|
US20050096266 |
Preparation and method for weight reduction
The present invention encompasses a preparation and method whereby a trypsin inhibitor and free essential amino acids are used simultaneously in the form of an oral preparation to reduce weight. |
|
|
US20140105898 |
APOPTOSIS-INDUCING MOLECULES AND USES THEREFOR
This invention relates generally to methods and agents for modulating adiposity-related conditions. More particularly, the present invention relates to the use of TRAIL death receptor agonists,... |
|
|
US20090118178 |
Y4 SELECTIVE RECEPTOR AGONISTS FOR THERAPEUTIC INTERVENTIONS
Y4 receptor agonist peptide selected from the group consisting of: [Ala30]PP2-36, [Thr30]PP2-36, Asn30]PP2-36, [Gln30]PP2-36, [Glu10]PP2-36, [Glu10,Leu17,Thr30]PP2-36, [Nle17,Nle30]PP2-36,... |
|
|
US20060205633 |
Therapeutic agent for diabetes
A pharmaceutical composition herein provided comprises at least one branched chain amino acid selected from the group consisting of isoleucine, leucine and valine, combined with at least one drug... |
|
|
US20100168020 |
STABILIZED RECEPTOR POLYPEPTIDES AND USES THEREOF
The present invention provides stabilized activin IIB receptor polypeptides and proteins capable of binding and inhibiting the activities of activin A, myostatin, or GDF-11. The present invention... |
|
|
US20100239554 |
EXTENDED RECOMBINANT POLYPEPTIDES AND COMPOSITIONS COMPRISING SAME
The present invention relates to compositions comprising biologically active proteins linked to extended recombinant polypeptide (XTEN), isolated nucleic acids encoding the compositions and... |
|
|
US20090155375 |
Compositions comprising a lipid and copolymer of styrene and maleic acid
A composition comprising a lipid and copolymer of styrene and maleic acid, wherein the copolymer of styrene and maleic acid is non-alternating, and wherein the polymer and lipid are in the form of... |
|
|
US20150196617 |
Peptide Analogs for Treating Diseases and Disorders
Provided herein are methods for the treatment of type I diabetes, Type II diabetes, metabolic syndrome, or obesity, or of appetite suppression, or for mitigating insulin resistance, or for... |
|
|
US20060216297 |
Method and composition for reducing blood sugar levels or fat storage by targeting cathepsin
Methods and compositions are provided for reducing blood sugar levels or fat storage of animals by targeting the gene and gene products of cathepsins, particularly cathepsins L, K, and S. The... |
|
|
US20140087995 |
Polypeptides
The invention relates to polypeptides comprising an amino acid sequence which is an analogue of human amylin, pharmaceutical compositions comprising these polypeptides, and these polypeptides for... |
|
|
US20130281363 |
POLYPEPTIDES
The invention relates to polypeptides comprising an amino acid sequence which is an analogue of human amylin, pharmaceutical compositions comprising these polypeptides, and these polypeptides for... |
|
|
US20070254314 |
Methods of treating autism and autism spectrum disorders
The present invention relates to methods of treating a subject diagnosed with autism or an autism spectrum disorder, lowering the level of mercury in a subject determined to contain a high level... |
|
|
US20090142259 |
Compositions and methods for the diagnosis and treatment of bladder and urinary tract tumors
The present invention is directed to methods of diagnosing and treating, as well as articles of manufacture useful for diagnosing and treating, bladder and/or urinary tract tumor in mammals. |
|
|
US20070265200 |
Glycol Linked Fgf-21 Compounds
The invention provides FGF-21 compounds covalently attached to at least one polyethylene glycol molecule or derivative thereof, resulting in a biologically active polypeptide with an extended... |
|
|
US20100113332 |
METHOD OF TREATING AN INFLAMMATORY DISEASE BY DOUBLE STRANDED RIBONUCLEIC ACID
What is disclosed is the use of a formulation comprising double stranded ribonucleic acid (dsRNA) in the manufacture of a medicament for treating an inflammatory disease in a mammal and inhibiting... |
|
|
US20130059770 |
POLYPEPTIDES
The invention relates to polypeptides comprising an amino acid sequence which is an analogue of pramlintide, pharmaceutical compositions comprising these polypeptides, and these polypeptides for... |
|
|
US20070128252 |
COMPOSITIONS AND METHODS FOR TREATMENT OF BODY WEIGHT CONDITIONS
A nutritional supplement composition having a therapeutically effective amount of peptides is provided for the treatment of body weight conditions. The nutritional supplement may also comprise... |
|
|
US20120208747 |
NOVEL PEPTIDE FOR AUGMENTING AND EXPRESSION OF BDNF AND PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF NEURODEGENERATIVE DISEASES INCLUDING ALZHEIMER'S DISEASE OR PARKINSON'S DISEASE, COMPRISING THE SAME
Disclosed are peptides for augmenting the expression of BDNF (brain-derived neurotrophic factor) and a pharmaceutical composition for the prevention and treatment of Alzheimer's disease or... |
|
|
US20130012432 |
Peptides for Treatment of Obesity
The present invention relates to novel peptide compounds which are effective in modulating one or more melanocortin receptor types, to the use of the compounds in therapy, to methods of treatment... |
|
|
US20120021973 |
Peptides for Treatment of Obesity
The present invention relates to novel peptide compounds which are effective in modulating one or more melanocortin receptor types, to the use of the compounds in therapy, to methods of treatment... |
|
|
US20100093604 |
Gpr43 and modulators thereof for the treatment of metabolic-related disorders
The present invention relates to a method for identifying a metabolic stabilizing compound by: a) contacting a candidate compound with GPR43, and b) determining whether GPR43 functionality is... |
|
|
US20120178668 |
PROTEINACEOUS COMPOUNDS AND USES THEREFOR
The present invention discloses proteinaceous compounds that comprise at least a biologically active portion of a taipan natriuretic peptide (TNP) or a variant or derivative thereof. The invention... |
|
|
US20060292186 |
Self-nanoemulsifying oily formulation for the administration of poorly water-soluble drugs
A pharmaceutical composition in a form of an anhydrous self-nanoemulsifying oily formulation comprising: one or more therapeutic agent(s) which have low solubility in water or are water-insoluble,... |
|
|
US20120178673 |
FAT ACCUMULATION SUPPRESSOR
A fat accumulation suppressor comprising as an active ingredient a whey protein hydrolysate is provided. The hydrolysate has a molecular weight range of no higher than 10 kDa and a main peak of... |
|
|
US20060228775 |
Differential expression of nucleic acid molecules
The present invention relates generally to nucleic acid molecules expressed at least in the hypothalamus, liver, mesenteric adipose tissue, or red gastrocnemius muscle conveniently identified... |